Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials
Authors:
- Victor L. SerebruanyVSVictor L. Serebruany
- Daniel AradiDADaniel Aradi
- Moo Hyun KimMKMoo Hyun Kim
- Dirk SibbingDSDirk Sibbing
- 1 November 2013
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 169 (3) , 225-228
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Early glycoprotein IIb‐IIIa inhibitors in primary angioplasty‐abciximab long‐term results (EGYPT‐ALT) cooperation: individual patient’s data meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Cangrelor: a review on its mechanism of action and clinical developmentExpert Review of Cardiovascular Therapy, 2009
- Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysisHeart, 2008
- Bivalirudin for Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa AntagonistsCirculation, 2001
- Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist TrialsClinical Cardiology, 2000
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988